• About us
• Contact

Advertisement

Organisation › Details

MeiraGTx (Group)

MeiraGTx (NASDAQ:MGTX) is a vertically integrated, clinical stage gene therapy company with four ongoing clinical programs and a broad pipeline of preclinical and research programs. MeiraGTx has core capabilities in viral vector design and optimization and gene therapy manufacturing, as well as a potentially transformative gene regulation technology. Led by an experienced management team, MeiraGTx has taken a portfolio approach by licensing, acquiring and developing technologies that give depth across both product candidates and indications. MeiraGTx’s initial focus is on three distinct areas of unmet medical need: inherited retinal diseases, severe forms of xerostomia and neurodegenerative diseases. Though initially focusing on the eye, salivary gland and central nervous system, MeiraGTx intends to expand its focus in the future to develop additional gene therapy treatments for patients suffering from a range of serious diseases. *

 

	Start	2018-10-05 existent
	Industry	gene therapy
	Industry 2	riboswitch technology
	Person	Forbes, Alexandria (MeiraGTx 201810 CEO)
	Person 2	Breedis, Katherine (MeiraGTx 201810– CFO before Stifel Nicolaus + Pfizer + Eli Lilly + Schroder + Goldman Sachs + Citi)
	Region	London, Greater London
	Country	United Kingdom (GB)
	Street	92 Britannia Walk
	City	N1 7NQ London
		Address record changed: 2020-12-02
Basic data	Employees	D: 101 to 500 (2022-12-31)
	Currency	USD
	Annual sales	15,920,000 (license revenue, related party, consolidated (2022) 2022-12-31)
	Profit	-129,615,000 (2022-12-31)
	Cash	115,516,000 (2022-12-31)
		* Document for »About Section«: MeiraGTx Holdings plc. (10/9/18). "Press Release: MeiraGTx Announces Acquisition of Vector Neurosciences, Gains Phase 2 Gene Therapy Program for Parkinson’s Disease". London & New York.
		Record changed: 2023-12-28

Advertisement

More documents for MeiraGTx (Group)

• [1] MeiraGTx Holdings plc. (10/30/23). "Press Release: MeiraGTx Announces $30 Million Strategic Investment from Sanofi; Company Pursuing Multiple Additional Strategic Opportunities". London & New York, NY....
• [2] MeiraGTx Holdings plc. (9/8/22). "Press Release: MeiraGTx to Participate in Upcoming Investor Conferences". London & New York, NY....
• [3] MeiraGTx Holdings plc. (11/19/20). "Press Release: MeiraGTx Announces Pricing of Public Offering of Ordinary Shares". London & New York, NY....
• [4] MeiraGTx Holdings plc. (8/8/19). "Press Release: MeiraGTx Announces Pricing of Public Offering of Ordinary Shares". London & New York, NY....
• [5] MeiraGTx Holdings plc. (8/7/19). "Press Release: MeiraGTx Reports Second Quarter 2019 Financial Results and Provides Corporate Update". London & New York, NY....
• [6] MeiraGTx Holdings plc. (8/7/19). "Press Release: MeiraGTx Announces Proposed Public Offering of Ordinary Shares". London & New York, NY....
• [7] MeiraGTx Holdings plc. (5/14/19). "Press Release: MeiraGTx Reports First Quarter 2019 Financial Results and Provides Corporate Update". London & New York, NY....
• [8] MeiraGTx Holdings plc. (5/14/19). "Press Release: MeiraGTx Announces Positive 6-Month Data from Phase 1/2 Trial of Investigational Gene Therapy AAV-RPE65 for RPE65-Deficiency". London & New York, NY....
• [9] MeiraGTx Holdings plc. (5/10/19). "Press Release: MeiraGTx Appoints Nicole Seligman to Board of Directors". London & New York, NY....
• [10] MeiraGTx Holdings plc. (5/6/19). "Press Release: MeiraGTx to Present at Bank of America Merrill Lynch Healthcare Conference". London & New York, NY....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2024. Made in Germany.